MINNEAPOLIS, Oct. 15, 2014 /PRNewswire/ -- Uroplasty, Inc.
(NASDAQ: UPI), a medical device company that develops, manufactures
and markets innovative proprietary products for the treatment of
voiding dysfunctions, announced today that Kenneth H. Paulus has been appointed to the
Company's Board of Directors effective October 15, 2014. Mr. Paulus will chair the
Board's compensation committee and serve on the nominating
committee.
Mr. Paulus currently serves as Chief Executive Officer of
Allina Heath, a Minnesota-based health system with more than
$3.5 billion in annual revenue.
Allina owns and operates 90 clinics, 12 hospitals and 15
pharmacies, with 5,000 employed and associated physicians and
26,000 employees.
Before joining Allina Health in 2005, Mr. Paulus was President
and Chief Executive Officer of Massachusetts-based HealthOne Care System, one
of the nation's largest integrated physician organizations and a
teaching and research affiliate of Harvard
Medical School. Before his time at HealthOne, he served as
the Chief Operating Officer of Boston-based Partners Community
HealthCare/Partners HealthCare System. Partners HealthCare System
is a teaching affiliate of Harvard Medical
School that includes two of the nation's leading hospitals -
Massachusetts General Hospital and Brigham and Women's
Hospital.
"Ken's experience as the leader of several large healthcare
delivery systems offers important perspective as we continue to
refine our strategy and expand our customer base," said
Rob Kill, Chairman & CEO of
Uroplasty. "In particular, his deep knowledge of the care
delivery system adds significant value as we continue strategic
R&D investments and evaluate expansion opportunities through
business development activities. We are excited that Ken has chosen
to join our Board and look forward to his substantive
contributions."
Mr. Paulus currently serves on the Board of Overseers for the
University of Minnesota Carlson School
of Business, is a trustee with Hamline
University, and serves on the executive committee and board
of directors for the Minnesota Hospital Association. He is a
graduate of the University of Minnesota
Masters Program in Healthcare Administration.
Uroplasty also reported that Tom
Jamison and Lee Jones have
resigned from the Board of Directors, effective October 15, 2014. "The Board would like to thank
Mr. Jamison and Ms. Jones for their combined 22 years of service
and contributions to Uroplasty," said Mr. Kill.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered
in Minnetonka, Minnesota, with
wholly-owned subsidiaries in the
Netherlands and the United
Kingdom, is a global medical device company that develops,
manufactures and markets innovative proprietary products for the
treatment of voiding dysfunctions. Our focus is the continued
commercialization of our Urgent® PC Neuromodulation System, which
we believe is the only commercially available, FDA-cleared system
that delivers percutaneous tibial nerve stimulation (PTNS) for the
office-based treatment of overactive bladder (OAB). OAB is a
chronic condition that affects approximately 42 million U.S.
adults. The symptoms include urinary urgency, frequency and
urge incontinence. We also offer Macroplastique®, an
injectable urethral bulking agent for the treatment of adult female
stress urinary incontinence primarily due to intrinsic sphincter
deficiency. For more information on the Company and its products,
please visit Uroplasty, Inc. at www.uroplasty.com.
For Further Information:
Uroplasty, Inc.
Brett Reynolds, SVP and CFO
952-426-6152
EVC Group
Brian Moore/Doug Sherk (Investors)
415-652-9100
Janine McCargo (Media)
646-688-0425
SOURCE Uroplasty, Inc.